FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380030108> ?p ?o ?g. }

• W4380030108 endingPage "546" @default.
• W4380030108 startingPage "546" @default.
• W4380030108 abstract "Abstract The mitogen-activating protein kinase (MAPK) pathway [RAS/RAF/MEK/MAPK] is a well-known mitogenic pathway essential for regulation of cell proliferation, survival, differentiation, invasion, and apoptosis, etc. In normal cells, upon the binding of external stimuli, activated Ras relays the signals through a RAF-MEK-ERK (MAPKKK-MAPKK-MAPK) phosphorylation cascade, leading to MAPK pathway activation. On the other hand, in cancer cells, aberrations or mutations of the pathway components usually could lead to constitutive activation of the pathway, resulting in dysregulation of these cellular processes. Notably, mutations of MAPK pathway components are found in 18% of head and neck cancer (HNC). Among these, mutations of the serine/threonine-protein kinase B-Raf (BRAF gene) account for about 1.8% of HNC (based on TCGA-HNSCC cohort, USA). Serving as one of the key kinase members of the MAPK pathway, BRAF is considered as a precision drug target in various cancer types, including melanoma, thyroid cancer, and non-small cell lung cancer (NSCLC). While the significance of BRAF mutations remains underexplored in HNC, exceptionally favorable responses to BRAF and MEK inhibition had been reported in HNC patients carrying BRAF-mutations. Based on this, we hypothesize that BRAF mutations may confer drug sensitivity and serve as a predictive biomarker for personalized therapy in HNC. Here, we demonstrated that ectopic overexpression of mutated BRAF resulted in MAPK pathway activation in HNC cell models. We also showed that ectopic BRAFV600E could promote the in vitro growth of head and neck cancer cells in both 2D and 3D culture conditions as well as enhance anoikis resistance, which is a prerequisite for metastasis. Further preliminary results showed that the mutated BRAFV600E mutant could promote the invasiveness of HNC cells. In summary, our findings support that targeting the BRAF mutants could be a potential therapeutic approach or precision treatment for HNC. (This study was supported by the Research Impact Fund (R4015-19F in the period of 6/29/2020-9/7/2021) from the Research Grants Council, University Grants Committee, Hong Kong SAR.) Citation Format: Chun Ho Law, Franky Leung Chan, Vivian Wai Yan Lui. Targeting BRAF mutations in head and neck cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 546." @default.
• W4380030108 created "2023-06-10" @default.
• W4380030108 creator A5012737253 @default.
• W4380030108 creator A5030534481 @default.
• W4380030108 creator A5039189891 @default.
• W4380030108 date "2023-04-04" @default.
• W4380030108 modified "2023-09-24" @default.
• W4380030108 title "Abstract 546: Targeting <i>BRAF</i> mutations in head and neck cancer" @default.
• W4380030108 doi "https://doi.org/10.1158/1538-7445.am2023-546" @default.
• W4380030108 hasPublicationYear "2023" @default.
• W4380030108 type Work @default.
• W4380030108 citedByCount "0" @default.
• W4380030108 crossrefType "journal-article" @default.
• W4380030108 hasAuthorship W4380030108A5012737253 @default.
• W4380030108 hasAuthorship W4380030108A5030534481 @default.
• W4380030108 hasAuthorship W4380030108A5039189891 @default.
• W4380030108 hasConcept C121608353 @default.
• W4380030108 hasConcept C126322002 @default.
• W4380030108 hasConcept C184235292 @default.
• W4380030108 hasConcept C2777658100 @default.
• W4380030108 hasConcept C2781230642 @default.
• W4380030108 hasConcept C2781249067 @default.
• W4380030108 hasConcept C2909378205 @default.
• W4380030108 hasConcept C502942594 @default.
• W4380030108 hasConcept C54355233 @default.
• W4380030108 hasConcept C57074206 @default.
• W4380030108 hasConcept C71924100 @default.
• W4380030108 hasConcept C81885089 @default.
• W4380030108 hasConcept C86803240 @default.
• W4380030108 hasConcept C95444343 @default.
• W4380030108 hasConcept C97029542 @default.
• W4380030108 hasConcept C97037327 @default.
• W4380030108 hasConceptScore W4380030108C121608353 @default.
• W4380030108 hasConceptScore W4380030108C126322002 @default.
• W4380030108 hasConceptScore W4380030108C184235292 @default.
• W4380030108 hasConceptScore W4380030108C2777658100 @default.
• W4380030108 hasConceptScore W4380030108C2781230642 @default.
• W4380030108 hasConceptScore W4380030108C2781249067 @default.
• W4380030108 hasConceptScore W4380030108C2909378205 @default.
• W4380030108 hasConceptScore W4380030108C502942594 @default.
• W4380030108 hasConceptScore W4380030108C54355233 @default.
• W4380030108 hasConceptScore W4380030108C57074206 @default.
• W4380030108 hasConceptScore W4380030108C71924100 @default.
• W4380030108 hasConceptScore W4380030108C81885089 @default.
• W4380030108 hasConceptScore W4380030108C86803240 @default.
• W4380030108 hasConceptScore W4380030108C95444343 @default.
• W4380030108 hasConceptScore W4380030108C97029542 @default.
• W4380030108 hasConceptScore W4380030108C97037327 @default.
• W4380030108 hasIssue "7_Supplement" @default.
• W4380030108 hasLocation W43800301081 @default.
• W4380030108 hasOpenAccess W4380030108 @default.
• W4380030108 hasPrimaryLocation W43800301081 @default.
• W4380030108 hasRelatedWork W2141202463 @default.
• W4380030108 hasRelatedWork W2164992866 @default.
• W4380030108 hasRelatedWork W2401574182 @default.
• W4380030108 hasRelatedWork W2767735945 @default.
• W4380030108 hasRelatedWork W2904474407 @default.
• W4380030108 hasRelatedWork W3126366955 @default.
• W4380030108 hasRelatedWork W4280561446 @default.
• W4380030108 hasRelatedWork W4362493042 @default.
• W4380030108 hasRelatedWork W4362495258 @default.
• W4380030108 hasRelatedWork W4378229285 @default.
• W4380030108 hasVolume "83" @default.
• W4380030108 isParatext "false" @default.
• W4380030108 isRetracted "false" @default.
• W4380030108 workType "article" @default.